29 results on '"Monzon, Jose"'
Search Results
2. The prognostic impact of immune-related adverse events in real-world patients with metastatic melanoma treated with single-agent and combination immune checkpoint blockade.
3. Pan-Canadian cohort of immune checkpoint inhibitor-induced insulin-dependent diabetes mellitus (CANDIED).
4. A cost-utility analysis of combined durvalumab and tremelimumab in patients with refractory metastatic colorectal cancer (mCRC) and high plasma tumour mutation burden (pTMB): A Canadian Cancer Trials Group (CCTG) study.
5. Adjuvant systemic therapies for melanoma in Alberta: An early descriptive analysis of population characteristics and treatment outcomes.
6. The impact of socioeconomic factors on outcomes of patients with locally advanced rectal cancer (LARC).
7. The population-based impact of new therapeutic eras on outcomes in advanced melanoma.
8. A stage versus stage survival analysis of small bowel and colon adenocarcinomas using the SEER database.
9. Phase 0 (Ph0) and Window-of-Opportunity (WoO) trial quality and reporting.
10. Impact of Canadian Cancer Trials Group (CCTG) phase III trials (P3Ts).
11. Pembrolizumab-induced immune related adverse events and survival outcomes in advanced melanoma.
12. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation.
13. Application of the ASCO framework for assessing value in metastatic colorectal cancer clinical trials.
14. A multicentre, open-label phase II study of irinotecan, capecitabine, and oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
15. Clinical effectiveness of adjuvant chemotherapy (AC) with or without oxaliplatin following neoadjuvant chemoradiotherapy (nCRT) in stage II rectal cancer (RC).
16. Critical assessment of phase 0 (Ph0) and window of opportunity (WOO) trials: Definitions and reporting.
17. Drug development for breast (BC), colorectal (CRC), and non-small cell lung cancers (NSCLC) over the past 34 years.
18. Trends in the design and interpretation of metastatic colorectal cancer phase III clinical trials.
19. Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: A retrospective observational cohort study.
20. External validation of the neoadjuvant rectal (NAR) score and Valentini prediction nomogram (VPN): A multicenter study.
21. The impact of clinical response to anti-CTLA4 treatment on overall survival (OS) in metastatic melanoma (MM).
22. Correlation between phase 2 clinical trial design and subsequent phase 3 outcome.
23. Association of adjuvant chemotherapy with clinical outcomes in patients treated with neoadjuvant chemoradiation for locally advanced rectal cancer.
24. Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer.
25. Efficacy of two ipilimumab (IPI) doses (10 vs. 3 mg/kg) in Alberta, Canada, tertiary cancer centers.
26. Predictors of pathologic complete response after neoadjuvant treatment for rectal cancer: A multicenter study.
27. Predictors of treatment interruption/dose reduction of neoadjuvant chemotherapy for rectal cancer: A multicenter study.
28. Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM).
29. Efficacy endpoints (EEPs) in melanoma randomized controlled adjuvant trials (RCATs).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.